ABSTRACT -Background -Intestinal secretagogues have been tested for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome. The class-effect of these type of drugs has not been studied. Objective -To determine the efficacy and safety of intestinal secretagogues for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome. 
INTRODUCTION
Chronic constipation (CC) as well as constipation-predominant irritable bowel syndrome (IBS-C) are very common conditions that constitute a frequent reason for referral to the general practitioner and the gastroenterology specialist (1) . These conditions are associated with a significant morbidity and an impaired quality of life (2) . Even though they are classified as different entities according to Rome criteria (3) , the physiological mechanisms behind CC and IBS-C share a common ground. Thus, a diminished contractile activity of the colonic muscular layer as well as alterations in water reabsorption or secretion through intestinal epithelium have been proposed as etiological mechanisms (4) . As a consequence, they have been regarded as potential targets for pharmacological therapy.
Conventional treatment for CC and IBS-C include changes in lifestyle, increase of fiber intake and the use of a myriad of laxatives (5) . It can also contemplate other therapies oriented to treat constipation-related symptoms, such as abdominal bloating or pain (6) . It is noteworthy that a significant proportion of patients will not experience an improvement with these measures. Over the last years, new therapeutic alternatives have been developed: new high-affinity 5-HT4 receptor agonists such as prucalopride have been successfully tested; however, previous experience with similar molecules may raise a concern regarding their safety (7) . Among these new alternatives, intestinal secretagogues have shown some promising results. These drugs are designed to increase intestinal fluid secretion, thus increasing bowel movement frequency as well as enhancing the amount of stool water (8) . These molecules can act at different points: linaclotide for instance is a guanylate cyclase-C agonist that activates the cystic fibrosis transmembrane conductance regulator in the intestinal epithelium (9) , whereas lubiprostone activates type 2 Chloride channels in the aforementioned cells (10) . The common pathway of these mechanisms is an increased release of chloride -and water -to the intestinal lumen.
These drugs have now been tested in different clinical settings for the treatment of both CC and IBS-C, and the preliminary results have triggered the development of drugs with similar mechanism of action, such as plecanatide or tenapanor (11) . The class-effect of these type of drugs has not been extensively studied. As a consequence, we sought to determine the efficacy and safety of intestinal secretagogues for the treatment of CC and IBS-C.
Outcome measures
The following outcomes were considered for analysis: three or more spontaneous bowel movements (SBM) per week, number of complete spontaneous bowel movements (CSBM) per week, SBM after medication administration, improvement in abdominal pain, global relief of symptoms. Since Rome IV criteria (3) disregard abdominal discomfort as a pivotal symptom for the definition of IBS, we decided that it should not be contemplated as an endpoint, even though most trials assessed this point in particular. Data were extracted as intention-to-treat analyses, in which all dropouts are assumed to be treatment failures, wherever trial reporting allowed this.
Statistical analysis
Meta-analysis was performed using REVMAN software (Review Manager Version 5.2. Copenhagen: The Nordic Cochrane Collaboration, 2012). Heterogeneity among studies was evaluated by means of chi square and I2 tests. A random-effects model was used to give a more conservative estimate of the effect of individual therapies, allowing for any heterogeneity among studies. Outcome measures were described as relative risk (RR) of achieving an improvement in the symptom under consideration. Also, 95% confidence intervals were calculated. Funnel plots were designed to evaluate possible publication bias. Numbers necessary to treat (NNT) were calculated.
RESULTS
Database Search yielded 520 bibliographic citations, as shown in FIGURE 1. Of these, 18 full texts were assessed for eligibility and 16 trials were finally included for analysis (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) , which enrolled 7658 patients.
The main characteristics of included trials are described in TABLE 1. One of the most challenging aspects of this systematic review was the heterogeneity in the assessment of experimental drugs efficacy: as a consequence, not every trial was included in the assessment of each of the endpoints considered for meta-analysis. Patients were not similar: from an etiologic point of view, we divided trials evaluating the efficacy and safety of intestinal secretagogues on patients with CC and with IBS-C. Furthermore, CC patients also included patients with opioid-induced constipation as well as constipation associated with Parkinson disease (21) and diabetes mellitus (25) . Methodological evaluation of included trials is described in 
Efficacy of intestinal secretagogues for patients with chronic constipation
Twelve randomized controlled trials assessed the efficacy of three drugs for CC patients: linaclotide ( (Miner 2017 ). Efficacy endpoints are described in FIGURE 2. Overall, intestinal secretagogues were better than placebo at achieving an increase in the number of CSBM per week [RR 1.87 (1.24-2.83), NNT 9] , also at achieving three or more SBM per week [RR 1.56 (1.31-1.85), NNT 6] and at inducing SBM after medication intake [RR 1.49 (1.07-2.06), NNT 6] . Additionally, patients treated with intestinal secretagogues experienced a more significant global relief of their symptoms compared to placebo [RR 1.78 (1.18-2.69), NNT 7] . In the cases where a significant heterogeneity was found, a sensitivity analysis was performed, showing no significant changes. 21-1.48) , NNT 9] . In the cases where a significant heterogeneity was found, a sensitivity analysis was performed, showing no significant changes.
Adverse events
A pooled analysis of the most frequent adverse events is detailed in TABLE 3. Overall, intestinal secretagogues showed to be safe drugs, without a significant proportion of serious adverse events reported. By far, the most common adverse event -which caused drop outs throughout most of the included studies -was diarrhea along with abdominal pain and nausea. 
DISCUSSION
Constipation -in the context of CC or IBS-C -can be a very challenging condition to treat, leading to an impaired quality of life in a non-neglectable proportion of patients (2) . One of the reasons for this difficulty in the treatment is the paucity of therapeutic alternatives available. Most of the treatment options consist of laxatives as well as bulky agents such as fiber, which constitute a heterogeneous group of medications directed towards increasing the amount of water in stools or increasing colonic wall motility. A meta-analysis by Lee-Robichaud et al. (28) showed that, among the afore-mentioned options, polyethylene glycol was the laxative that showed more consistent results in terms of both efficacy and safety for the treatment of CC. Nevertheless, available alternatives other than laxatives are not abundant. Agents that promote adequate colonic motility such as 5-HT agonists have not been widely used until recently, mainly due to the concerns related to their potential cardiac side effects -as shown by the cisapride experience (7) . Prucalopride -a selective 5-HT4 agonist -has been approved by the European Medicines Agency for the treatment of CC due to its safety profile, showing no cardiac adverse events. Although prucalopride has expanded the therapeutic horizons for the treatment of CC or IBS-C, it may not be suitable or effective for every case that do not respond to laxatives or dietary measures.
Intestinal secretagogues are a type of medications whose mechanism of action implicates an increased amount of water excreted through the colonic epithelium. This is achieved by different means: linaclotide is a guanylate-cyclase agonist, whereas lubiprostone activates CIC-2 chloride channels, leading to the above-mentioned effect. Both plecanatide and tenapanor have been recently tested: plecanatide is also a guanylate-cyclase agonist like linaclotide (26) ; tenapanor in change inhibits sodium intake by intestinal epithelial cells, by inhibiting the sodium-proton exchanger NHE3 (27) . According to our result, regardless of the molecular approach these drugs have, intestinal secretagogues are more effective than placebo for the treatment of CC and IBS-C. This conclusion becomes relevant since evidently the mechanism exerted by these drugs is an effective one, thus it may provide significant information towards the design of new drugs with a similar mechanism. Moreover, these drugs seem to have acceptable safety profiles: there is a logical increase in the risk of gastrointestinal symptoms, which do not seem to represent a major threat to the patients under treatment.
Some interesting points should be mentioned when analyzing this systematic review. First of all, even though all of the clinical trials involved showed high quality from a methodological point of view, a non-neglectable heterogeneity in terms of outcome measurement was observed. With the exception of two trials (16, 17) which adopted Food and Drug Administration's suggested endpoints, none of the included studies evaluated the outcomes in a uniform fashion -this is a relevant point when it comes to comparing the results of different trials and when meta-analyses are performed. An effort should be made for future trials to reach a consensus regarding endpoint consideration and measurement.
On the other hand, there is relevant information which has not been exhaustively assessed. As highlighted in TABLE 1, the vast majority of patients were allowed to receive rescue medications; and even though intestinal secretagogues showed a better performance in every single endpoint under consideration, the comparison of the amount of rescue medicine needed in both therapeutic arms becomes a valuable piece of information in a clinical scenario in which most endpoints are subjective -this information is not present in most of the clinical trials.
According to our results, it becomes clear that intestinal secretagogues are a useful tool for the treatment of CC and IBS-C. However, the exact place in the therapeutic algorithm of constipation-related syndromes is not clear. Placebo-controlled trials do not answer the question of whether these drugs are suitable to become first-line therapies. For this purpose, head to head comparisons between experimental drugs and standard of care treatments (such as polyethylene glycol for instance) are needed. There is a noticeable lack of evidence involving head to head comparisons: a network meta-analysis (with its obvious limitations) did not find any advantage among therapeutic alternatives for CC (29) . This network meta-analysis can arguably replace the need for non-inferiority clinical trials comparing different therapeutic approaches -prokinetics, laxatives, intestinal secretagogues. In conclusion, intestinal secretagogues are both useful and safe for the treatment of both CC and IBS-C. A significant heterogeneity in terms of outcome measurement was observed, which can be detrimental for pooled analysis and therefore efforts should be made towards unifying endpoint selection criteria. Finally, head to head comparisons are necessary in order to establish a stepwise algorithm for the management of patients with CC and IBS-C.
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